Lv11
80 积分 2025-07-17 加入
Unlocking the potential of T cell engagers in solid tumors
13天前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
13天前
已完结
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers
16天前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
16天前
已完结
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
16天前
已完结
Selective RET Kinase Inhibitors and Lung Cancer
17天前
已完结
Selective Targeting of RET Fusions in Lung Cancer
17天前
已完结
Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC
17天前
已完结
Selective RET Kinase Inhibitors and Lung Cancer
17天前
已完结
Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis
19天前
已完结
皖公网安备34019202002308
